< Return to Class Actions List

A proposed class action has been commenced against GlaxoSmithKline Inc. and related companies ("GSK") relative to the drug Rosiglitazone (rosiglitazone maleate) which is widely used to lower blood sugar levels in people who suffer from Type II diabetes mellitus.  Rosiglitazone is marketed and sold by GSK under the brand names Avandia®, Avandamet®, and Avandaryl®.

Avandia was approved for distribution and sale in Canada in or about March 2000.  In or about November 2007, GSK issued a public communication informing the Canadian public of new restrictions on use of Avandia®, Avandamet®, and Avandaryl® and amended its product labelling based on a Health Canada review of information available on cardiovascular (heartrelated) safety.

Anyone who took this drug and who alleges that he/she have developed adverse cardiovascular side effects including heart attack, high blood pressure, stroke, heart failure, as well as vision problems, liver injury and/or failure, weakened bone strength and primary pulmonary hypertension (PPH) may participate in this action. 

Avandia®, Avandamet®, and Avandaryl® are registered trademarks of SmithKline Beecham (Cork) Limited and are used here only to identify the product in question.

< Return to Class Actions List